Vascular Endothelial Cell Induction via Matrix Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to efficiently induce highly functional vascular endothelial cells from pluripotent stem cells with high purity, limiting their therapeutic application in treating ischemic diseases.
Innovation Solution
A method involving culturing pluripotent stem cells on specific matrices, such as Matrigel or laminin-511, followed by dissociation and further culture on laminin-411 or its fragments, particularly laminin-411 E8, in the presence of BMP4 and VEGF, to induce mesodermal progenitor cells and subsequently vascular endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation methods are used, then vascular endothelial cells can be obtained, but the purity and functionality are insufficient for therapeutic applications
Solution Approach 1:
The differentiation process is divided into three distinct stages: (1) induction to mesodermal progenitor cells using BMP4 and specific matrix coating, (2) expansion of mesodermal progenitor cells with maintained differentiation potential, and (3) differentiation to vascular endothelial cells using VEGF and endothelial cell-specific matrix. This segmentation allows optimization of each stage independently to achieve both high purity and high efficiency
Solution Approach 2:
The method performs preliminary action by first inducing mesodermal progenitor cells with specific characteristics (self-renewal capacity and differentiation potential) before proceeding to vascular endothelial cell differentiation. This preliminary establishment of progenitor cells with optimized properties enables subsequent high-efficiency differentiation to pure vascular endothelial cells
2Reliability
If autologous EPCs are obtained from patient blood or bone marrow, then transplantation therapy can be performed, but the number and function are often decreased insufficient for therapeutic effect
Solution Approach 1:
The method performs preliminary action by first inducing mesodermal progenitor cells with specific characteristics (self-renewal capacity and differentiation potential) before proceeding to vascular endothelial cell differentiation. This preliminary establishment of progenitor cells with optimized properties enables subsequent high-efficiency differentiation to pure vascular endothelial cells
Solution Approach 2:
The invention changes key parameters including matrix composition (specific laminin isoforms), growth factor concentrations (BMP4, VEGF), and culture conditions to optimize both the quantity and quality of vascular endothelial cells produced, enabling sufficient cell numbers for therapeutic applications
3Productivity
If pluripotent stem cells are differentiated into vascular endothelial cells, then unlimited cell supply is possible, but current methods achieve low efficiency and purity
Solution Approach 1:
The differentiation process is divided into three distinct stages: (1) induction to mesodermal progenitor cells using BMP4 and specific matrix coating, (2) expansion of mesodermal progenitor cells with maintained differentiation potential, and (3) differentiation to vascular endothelial cells using VEGF and endothelial cell-specific matrix. This segmentation allows optimization of each stage independently to achieve both high purity and high efficiency
Solution Approach 2:
Mesodermal progenitor cells serve as an intermediary stage between pluripotent stem cells and vascular endothelial cells. These intermediary cells possess optimized properties (self-renewal and differentiation potential) that enable efficient and pure differentiation to the final therapeutic cell type
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the efficient production of highly functional vascular endothelial cells with high purity, suitable for therapeutic use in treating ischemic diseases like coronary artery diseases and lower limb ischemic diseases.
Implementation Method 1
a second matrix selected from the group consisting of laminin-411 or a fragment thereof, laminin-511 or laminin-511 E8, wherein the fragment of laminin-411 is a fragment having an avidity for integrin α6β1
Implementation Method 2
a step of culturing pluripotent stem cells in a culture medium comprising a BMP, on a culture vessel coated with a first matrix, to produce mesodermal progenitor cells
Implementation Method 3
a step of culturing the cells obtained in the step (ii) in a culture medium comprising VEGF, on a culture vessel coated with a second matrix
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
Provided is a method for producing vascular endothelial cells from pluripotent stem cells, the method comprising the following steps (i) to (iii): (i) a step of culturing pluripotent stem cells in a culture medium comprising a BMP, on a culture vessel coated with a first matrix, to produce mesodermal progenitor cells; (ii) a step of dissociating the resulting cells into single cells; and (iii) a step of culturing the resulting cells in a culture medium comprising VEGF, on a culture vessel coated with a second matrix selected from the group consisting of laminin-411 or a fragment thereof, laminin-511 or a fragment thereof, Matrigel, type IV collagen and fibronectin.